Cancer is not a single, uniform disease. Even within one tumor, thousands or millions of cells can differ in their genetic makeup, gene activity, cellular state, metabolism, and interactions with surrounding tissues. This biological diversity—known as cancer heterogeneity—is one of the major reasons why tumors can behave differently, respond unevenly to treatment, and develop resistance.

For years, researchers primarily studied tumors using bulk sequencing, which averages molecular signals across large groups of cells. Although useful, this approach can hide rare cancer cell populations and important differences between individual cells.

Single-cell multiomics is changing that picture. By measuring multiple molecular features at single-cell resolution, researchers can investigate how genetic alterations, chromatin accessibility, gene expression, cellular states, and regulatory programs interact within individual tumor cells.

In 2026, the field is moving beyond simply cataloguing cancer cell types. New research is increasingly connecting genotype with phenotype, mapping tumor evolution, studying cellular plasticity, identifying regulatory mechanisms behind metastasis and treatment resistance, and combining single-cell information with spatial and clinical data. Recent work published in Nature Reviews Cancer describes multimodal single-cell technologies as an important route toward understanding how cancer clones evolve and how their molecular characteristics influence disease behavior. For broader context on cancer research advances, see What's Next in Cancer Treatment: Advances Beyond Immunotherapy.

This blog explores the latest developments in single-cell multiomics, how the technology is revealing cancer heterogeneity, its emerging applications in precision oncology, and the challenges that still need to be addressed before these technologies become routine clinical tools.

What Is Single-Cell Multiomics?

Single-cell multiomics refers to technologies that measure multiple molecular layers from individual cells or integrate different single-cell measurements.

Traditional single-cell RNA sequencing primarily measures gene expression. Multiomic approaches can combine information from several biological layers, including:

  • DNA mutations and copy-number alterations
  • RNA expression
  • Chromatin accessibility
  • DNA methylation
  • Protein expression
  • Cellular surface markers
  • Epigenetic states
  • Spatial information

The advantage is that researchers can study not only what genes are active, but also investigate the regulatory and genetic features associated with those expression patterns.

Why Single-Cell Resolution Matters

A tumor sample may contain:

  • Malignant cells
  • Immune cells
  • Fibroblasts
  • Endothelial cells
  • Stromal cells
  • Cancer stem-like populations
  • Rare resistant cell populations

Bulk sequencing combines signals from these different populations.

Single-cell analysis separates them, allowing researchers to ask more specific questions:

Which cells carry a particular mutation?

Which cells express resistance-associated genes?

Which cellular states are associated with invasion?

How do cancer cells interact with immune and stromal populations?

This cellular resolution is particularly valuable for understanding tumor heterogeneity.

Understanding Cancer Heterogeneity

Cancer heterogeneity describes the biological differences that exist within and between tumors.

It can occur at several levels.

Genetic Heterogeneity

Different cancer cells may carry different mutations or copy-number alterations. This can produce distinct cellular clones within the same tumor.

Epigenetic Heterogeneity

Cancer cells can also differ in:

  • Chromatin accessibility
  • DNA methylation
  • Histone-associated regulation
  • Gene regulatory activity

These differences can affect which genes are turned on or off.

Transcriptional Heterogeneity

Cells with similar genetic alterations may still show different gene-expression patterns. This means that the same mutation does not necessarily produce an identical cellular state in every cancer cell.

Microenvironmental Heterogeneity

Cancer cells exist within a tumor ecosystem containing immune cells, blood vessels, fibroblasts, extracellular matrix, and other components. The local environment can influence cancer-cell behavior.

Modern single-cell and spatial profiling approaches are increasingly being used to investigate these interacting cellular ecosystems.

Medical Journal IMJ Health Call for Papers

How Single-Cell Multiomics Reveals Tumor Diversity

Single-cell multiomics provides a multidimensional view of cancer.

Instead of asking only "Which genes are expressed?", researchers can investigate:

Which genetic alterations are present, which regulatory regions are active, which genes are expressed, and what cellular state results?

This integrated perspective can reveal relationships that may be difficult to identify using a single molecular layer.

Linking Genotype With Phenotype

One of the major developments in 2026 is the increasing ability to connect genetic alterations with cellular characteristics within the same cell or cellular lineage.

A September 2026 review in Nature Reviews Cancer highlights how multimodal single-cell technologies can reveal mutant-specific phenotypes, identify cell-state-specific effects of genetic changes, and combine phylogenetic reconstruction with phenotypic measurements to study clonal evolution.

This is important because researchers want to understand not only which mutations exist, but also what those mutations actually make cancer cells do.

Latest Research: Mapping Cancer Cell States

Recent studies increasingly show that cancer cells should not always be classified into simple categories.

Cancer cells can move between different biological states.

These transitions may influence:

  • Tumor growth
  • Invasion
  • Metastasis
  • Treatment response
  • Drug resistance

Single-cell multiomics provides an opportunity to investigate these transitions at much higher resolution.

EMT and Cancer Cell Plasticity

One major example is the epithelial-to-mesenchymal transition (EMT).

EMT is associated with changes in cell identity and behavior and has been linked to cancer invasion, metastasis, and therapy resistance.

A 2026 Nature Communications study combined single-cell RNA sequencing with single-cell ATAC sequencing to map transcriptional and chromatin landscapes across different EMT states in a mouse model of skin squamous cell carcinoma. The researchers identified transcription factors associated with specific stages of EMT and experimentally investigated their roles using CRISPR/Cas9-based approaches.

The findings reinforce the concept that EMT is better understood as a spectrum of cellular states rather than a simple on/off switch.

Pan-Cancer Single-Cell Multiomics

Another important direction is the construction of large single-cell datasets covering multiple cancer types.

A 2026 Nature Communications study created a pan-cancer single-cell atlas of 60 cancer cell lines across 20 cancer types, combining more than 240,000 single-nucleus RNA-sequencing profiles with more than 223,000 single-nucleus ATAC-sequencing profiles.

The analysis identified:

  • Cancer cell-state heterogeneity
  • Gene-regulatory networks
  • Shared regulatory programs
  • Lineage-specific states
  • An epithelial–mesenchymal transition axis across cancer contexts

The study also investigated how transcription-factor amplification and regulatory activation can influence cancer cell states.

Such datasets could help researchers distinguish regulatory mechanisms that are shared across cancers from those that are specific to particular tumor types.

Single-Cell Multiomics and Cancer Evolution

Cancer evolves over time.

As tumor cells divide and acquire additional molecular changes, different clones can expand or disappear.

Treatment itself can create a selection pressure, allowing resistant populations to survive.

Single-cell multiomics can help reconstruct aspects of this evolutionary process.

Clonal Evolution

Researchers can investigate:

  • Which clones are expanding
  • Which mutations occur earlier or later
  • How cellular states change during evolution
  • Which populations survive treatment

This provides a more dynamic view of cancer biology.

Therapy Resistance

A small resistant population may be difficult to detect using bulk analysis.

Single-cell approaches can potentially identify these populations before they become dominant.

Understanding resistant states could support research into combination treatments or strategies designed to prevent resistant clones from expanding. For related insights on treatment resistance, see ADC Combination Strategies: Latest Research on Synergistic Therapies in Solid Tumors.

Studying the Tumor Microenvironment

Cancer cells do not exist in isolation.

The tumor microenvironment (TME) contains many other cell types that influence tumor behavior.

Single-cell technologies can characterize:

  • T cells
  • B cells
  • Macrophages
  • Fibroblasts
  • Endothelial cells
  • Dendritic cells
  • Other stromal populations

Researchers can then investigate how these populations interact.

Cancer–Immune Interactions

Understanding immune-cell states is particularly important for immunotherapy.

Single-cell analysis may reveal:

  • Activated immune populations
  • Exhausted T-cell states
  • Immunosuppressive populations
  • Tumor-associated macrophage states

This information can help researchers investigate why some tumors respond to immunotherapy while others do not. For related insights, see The Challenges and Opportunities in Immunotherapy Research.

From Single-Cell to Spatial Multiomics

A major development beyond conventional single-cell sequencing is spatial biology.

Traditional single-cell sequencing can provide detailed molecular information but may lose the exact location of cells within the tissue.

Spatial technologies attempt to preserve that information.

Researchers can ask:

Where is this cell located?

Which cells are next to it?

What molecular programs are active in that neighborhood?

Recent 2026 reviews describe spatial and single-cell profiling as complementary technologies for understanding tumor ecosystems, drug response, resistance, and target discovery.

3D Multiomics Tumor Atlases

Research is also moving toward three-dimensional representations of tumors.

A 2026 Nature Reviews Cancer review describes emerging 3D multiomics tumor atlases designed to capture cellular interactions across space and time. These approaches aim to study precancerous lesions, tumor development, invasion, and metastasis within their three-dimensional tissue environments.

Potential applications include:

  • Early cancer detection
  • Risk stratification
  • Biomarker discovery
  • Understanding metastasis
  • Treatment planning

This represents an important shift from studying isolated molecular measurements toward understanding cancer as a spatially organized ecosystem.

AI and Single-Cell Multiomics

The enormous amount of data generated by multiomics creates another challenge: how can researchers interpret it effectively?

Artificial intelligence and machine learning are increasingly being used to analyze complex biological datasets.

AI can assist with:

  • Cell classification
  • Pattern recognition
  • Biomarker discovery
  • Molecular data integration
  • Cellular trajectory analysis
  • Patient stratification

A 2026 Nature Reviews Cancer review describes AI as increasingly important for integrating multiomics with clinical information and imaging, with applications in patient stratification, treatment-response prediction, and investigation of drug resistance. For broader context, see The Role of Artificial Intelligence in Medical Research.

New Computational Approaches for Cancer Heterogeneity

Computational methods are also being developed to connect single-cell measurements with patient-level information.

A September 2026 Nature Communications study introduced scTransMIL, a transformer-based multi-instance learning framework designed to connect single-cell transcriptomic profiles with sample-level cancer phenotypes. The researchers reported applications including tissue-of-origin prediction for metastatic tumors, identification of tumor-associated populations, progression trajectories, and transcriptome-level biomarker discovery.

This illustrates an important direction for the field: moving from detailed cellular datasets toward models that can connect cellular patterns with clinically meaningful characteristics.

Potential Applications in Precision Oncology

Single-cell multiomics is not yet a universal clinical test, but its research applications are expanding.

Biomarker Discovery

Researchers can identify molecular signatures associated with:

  • Disease progression
  • Treatment response
  • Resistance
  • Metastatic potential

Patient Stratification

Patients who appear similar using conventional clinical classifications may have very different tumor biology. Multiomic profiling may eventually help define more biologically meaningful subgroups. For related insights, see AI in Clinical Trial Design: Latest Research on Optimizing Patient Stratification and Endpoints.

Drug Target Discovery

Identifying pathways that are specifically active in aggressive or resistant cell populations may reveal potential therapeutic targets.

Monitoring Treatment Response

Repeated molecular profiling could potentially help researchers study how tumors change during therapy.

Challenges and Limitations

Despite its enormous potential, single-cell multiomics still faces important challenges.

High Cost

Multiomic experiments can require sophisticated instruments, reagents, sequencing infrastructure, and computational resources.

Complex Data Analysis

Combining multiple molecular layers creates highly complex datasets.

Sample Quality

Tumor samples can change during collection, preservation, and processing. These factors can influence results.

Limited Clinical Standardization

Different platforms and analytical pipelines can produce different results. Standardized workflows remain important for clinical translation.

Data Integration

Integrating molecular information with pathology, imaging, clinical records, and treatment history remains technically challenging.

Interpretation

Finding a molecular association does not automatically demonstrate that it causes a cancer behavior. Functional experiments are often required to validate biological mechanisms.

Recent reviews emphasize sample acquisition, preservation, profiling technologies, computational methods, reproducibility, and clinical implementation as important barriers to wider clinical adoption.

Ethical and Data Considerations

As single-cell technologies become more sophisticated, researchers must also address:

  • Patient privacy
  • Genomic data protection
  • Responsible data sharing
  • Informed consent
  • Algorithmic bias
  • Reproducibility

The integration of genomic, clinical, imaging, and longitudinal data creates particularly important data-governance considerations.

The Future of Single-Cell Multiomics

The field is moving toward increasingly integrated cancer maps.

Future research is likely to combine:

  • Single-cell genomics
  • Transcriptomics
  • Epigenomics
  • Proteomics
  • Spatial biology
  • Imaging
  • Clinical data
  • AI-based analysis

The goal is to develop a more complete understanding of each tumor's cellular ecosystem.

Researchers may increasingly move from static tumor descriptions toward dynamic models of cancer evolution, tracking how individual cellular populations change over time and respond to treatment.

AI-driven multiomics may also contribute to patient-specific disease modeling and precision oncology. Current 2026 research reviews discuss the possibility of integrating multiomics with clinical and imaging information and eventually developing patient-specific computational models, although substantial validation challenges remain.

Single-cell multiomics is transforming cancer research by revealing biological differences that can remain hidden when tumor samples are analyzed as a single population. By connecting genetic, epigenetic, transcriptional, protein, and spatial information, researchers can investigate cancer heterogeneity with unprecedented cellular detail.

The latest 2026 research is increasingly focused on genotype–phenotype relationships, clonal evolution, EMT states, tumor–immune interactions, spatial organization, and AI-assisted interpretation. Recent studies have also demonstrated the value of large pan-cancer multimodal atlases and computational frameworks that connect single-cell information with patient-level cancer characteristics.

The technology is still moving from research laboratories toward broader clinical implementation. Challenges involving cost, standardization, sample quality, data interpretation, reproducibility, and clinical validation remain important.

Nevertheless, single-cell multiomics is helping redefine cancer as a dynamic ecosystem of genetically and functionally diverse cells. As multiomic technologies, spatial profiling, and AI continue to mature, they could provide increasingly detailed insights into why tumors evolve, metastasize, resist treatment, and respond differently across patients. For those considering doctoral research in this area, Top 10 Pharmaceutical Research Topics for PhD offers guidance on selecting impactful research directions.

Continue Exploring Our Blog